Drug Discovery
By
Could AbbVie and IGI’s $1.9B Bet on AI-Engineered Trispecific Antibody Signal a New Era for Relapsed Myeloma Treatment?
Key Highlights: AbbVie Accelerates into AI-Powered Immuno-OncologyAbbVie has entered a global licensing agreement worth up to $1.925 billion…
Will AI-Powered Querent™ by Mango Sciences Transform Veeda Lifesciences’ Global Clinical Trial Efficiency?
Key Highlights AI-Driven Precision in Global Trial RecruitmentVeeda Lifesciences, a global CRO, has announced a strategic investment in…
Can Revolution Medicines and Iambic’s AI Alliance Accelerate the Discovery of Next-Gen Cancer Drugs Targeting RAS Mutations?
Key Highlights AI-Powered Discovery for RAS-Addicted CancersRevolution Medicines, a leader in targeting RAS-driven cancers, is turning to artificial…
At VivaTech 2025, Can NVIDIA, Sanofi, and TetraScience Unlock the Full Potential of Scientific AI Despite a 20-Exabyte Data Barrier?
Key Highlights The 20-Exabyte Problem: Data, Not Models, Is the Limiting FactorAt The Rise of Scientific AI panel…
Pfizer Secures Exclusive Global Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
Key Highlights A Bold Bet on BispecificsIn a significant expansion of its oncology pipeline, Pfizer has obtained exclusive…
Can AstraZeneca’s Imfinzi Redefine Gastric Cancer Treatment With FDA Priority Review Backing?
Key Highlights A New Chapter for Immunotherapy in Early-Stage GI CancersAstraZeneca’s Imfinzi is poised to become the first…
